<DOC>
	<DOCNO>NCT02391038</DOCNO>
	<brief_summary>The purpose study evaluate effect MLN0264 previously treat Asian participant Advanced Gastrointestinal ( GI ) Carcinoma ( Phase 1 ) Metastatic Recurrent Gastric Gastroesophageal Junction Adenocarcinoma ( Phase 2 ) Expressing Guanylyl Cyclase C ( GCC ) .</brief_summary>
	<brief_title>MLN0264 Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma Metastatic Recurrent Gastric Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C</brief_title>
	<detailed_description>The drug test study call MLN0264 . This drug evaluate check effect previously treat Asian individual Advanced GI Carcinoma ( Phase 1 ) Metastatic Recurrent Gastric Gastroesophageal Junction Adenocarcinoma ( Phase 2 ) . The study enroll approximately 95 participant . In Phase 1 , approximately 14 Asian participant GI malignancy enrol 3 plan dose cohort accord traditional 3 + 3 dose escalation scheme . The start dose 1.2 mg/kg MLN0264 administer IV Day 1 3-week cycle 1 year disease progression unacceptable toxicity occur . Dose escalation take place Phase 2 recommend dose determine . In Phase 2 , eligible Asian participant advance metastatic adenocarcinoma stomach gastroesophageal junction enrol . Participants must fail least 2 line prior anticancer therapy advance metastatic disease . Disease recurrence within 6 month last dose post-surgical adjuvant chemotherapy count 1 line prior anticancer therapy advance disease . This multi-center trial conduct Japan , Korea Taiwan . The overall time participate study 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Has Diagnosis GI carcinoma Immunohistochemistry/ Immunohistochemical ( IHC ) evidence expression GCC protein ( Hscore 10 great ) , standard treatment longer effective offer curative lifeprolonging potential . Has complete prior chemotherapy , immunotherapy radiation therapy least 4 week prior enrollment ( except Avastin [ bevacizumab ] least 8 week last administration elapse prior enrollment ) . Histologically confirm metastatic advance inoperable adenocarcinoma stomach gastroesophageal junction IHC evidence expression GCC indicate Hscore 10 great . Has complete prior chemotherapy , immunotherapy radiation therapy least 4 week prior enrollment . Has measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 guideline . Has Eastern Cooperative Oncology Group performance status 0 1 ( within 14 day prior enrollment ) . Females must 1year postmenopausal , even surgically sterile , agree use acceptable form birth control . Has adequate organ hematological function . Has resolution toxic effect prior treatment except alopecia Grade 0 1 National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) version 4.03 Has Concurrent treatment treatment within 4 week study entry investigational agent . Female participant lactation period , even discontinue breastfeed , positive pregnancy test Screening period . Has uncontrolled , clinically significant , symptomatic cardiovascular disease within 6 month prior enrollment . Has treatment medication clinically relevant potential risk prolong QT interval induce Torsades de Pointes discontinue switched different medication prior start study drug . Participants electrocardiogram ( ECG ) abnormality consider investigator clinically significant , repeated baseline prolongation ratecorrected QT interval millisecond ( msec ) electrocardiograph ( QTc ) . Ongoing clinically significant active infection . Has sign peripheral neuropathy . Concomitant chemotherapy , hormonal therapy , immunotherapy , form cancer treatment . Use strong cytochrome P450 ( CYP ) 3A4 inhibitor within 2 week first dose study drug . Has preexist medical condition sufficient severity prevent full compliance study . Has past concurrent history neoplasm GI carcinoma ( phase 1 ) gastric adenocarcinoma ( phase 2 ) , except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri . Known diagnosis human immunodeficiency virus ( HIV ) infection . Has asymptomatic brain metastasis . Has alcohol substance abuse disorder . Has positive test hepatitis B surface antigen . History hypersensitivity ingredient MLN0264 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MLN0264</keyword>
	<keyword>Advanced gastrointestinal carcinoma</keyword>
</DOC>